Supplemental Table S1.
Drugs | Study | Study population/subgroups | Number of subjects (n) | Approved 12-week regimen |
---|---|---|---|---|
DCV | ALLY-2 | GT1, TN/TE, ±cirrhosis, HCV/HIV co-infection | 127 | DCV + SOF |
EBR and GZR | C-EDGE co-infection | GT1a without baseline NS5A polymorphisms/GT1b, TN, ±cirrhosis, HCV/HIV co-infection | 179 | EBR/GZR |
C-EDGE TE | GT1a without baseline NS5A polymorphisms/GT1b, TE, ±cirrhosis, HCV mono-infection or HCV/HIV co-infection | 86 (80 mono-infections, 6 co-infections) | EBR/GZR | |
C-EDGE TN | GT1a without baseline NS5A polymorphisms/GT1b, TN, ±cirrhosis | 267 | EBR/GZR | |
C-SALVAGE | GT1a without baseline NS5A polymorphisms/GT1b, TE, ±cirrhosis | 76 | EBR/GZR + ribavirin (RBV) | |
C-SURFER | GT1a without baseline NS5A polymorphisms/GT1b, TN/TE, ±cirrhosis, severe renal impairment | 115 | EBR/GZR | |
LDV and SOF | ION-1 | GT1, TN, ±cirrhosis | 213 | LDV/SOF |
ION-2 | GT1, TE, without cirrhosis | 87 | LDV/SOF + RBV | |
ION-3 | GT1, TN, without cirrhosis | 216 | LDV/SOF | |
ION-4 | GT1, TN/TE, ±cirrhosis, HIV/HCV co-infection | 327 | Same as mono-infection | |
GLE and PIB | Expedition-1 | GT1, TN/TE (PRS), with cirrhosis | 90 | GLE/PIB |
Expedition-4 | GT1, TN/TE (PRS), ±cirrhosis, severe renal impairment | 55 | GLE/PIB | |
Magellon-1 | GT1, TE (NS3/4A PI), ±cirrhosis | 25 | GLE/PIB | |
OBV and PTV-r + DAS | PEARL-II | GT1b, TE, without cirrhosis | 91 | OBV/PTV-r + DAS |
PEARL-III | GT1b, TN, without cirrhosis | 209 | OBV/PTV-r + DAS | |
PEARL-IV | GT1a, TN, without cirrhosis | 100 | OBV/PTV-r + DAS + RBV | |
SAPPHIRE-I | GT1a, TN, without cirrhosis | 322 | OBV/PTV-r + DAS + RBV | |
SAPPHIRE-II | GT1a, TE, without cirrhosis | 173 | OBV/PTV-r + DAS + RBV | |
TURQUOISE I | GT1, TN/TE, ±cirrhosis, HCV/HIV co-infection | 25 | Same as mono-infection | |
TURQUOISE III | GT1b, TN/TE, with cirrhosis | 60 | OBV/PTV-r + DAS | |
SMV | COSMOS | GT1, TN/TE, without cirrhosis | 21 | SMV + SOF |
OPTIMIST-1 | GT1, TN/TE, without cirrhosis | 155 | SMV + SOF | |
SOF and VEL | ASTRAL-1 | GT1, TN/TE, ±cirrhosis | 328 | SOF/VEL |
ASTRAL-5 | GT1, TN/TE, ±cirrhosis, HIV co-infection | 78 | SOF/VEL | |
SOF, VEL and VOX | Polaris-1 | GT1, TE, ±cirrhosis | 150 | SOF/VEL/VOX |
Polaris-4 | GT1a, TE, ±cirrhosis | 36 | SOF/VEL/VOX |
DAS: dasabuvir; DCV: daclatasvir; EBR: elbasvir; GLE: glecaprevir; GT1: genotype 1; GZR: grazoprevir; HCV: hepatitis C virus; LDV: ledipasvir; NS3/4A PI: HCV NS3/4A protease inhibitor; NS: HCV nonstructural protein; OBV: ombitasvir; PIB: pibrentasvir; PRS: Prior treatment experience with regimens containing (peg) interferon, ribavirin, and/or sofosbuvir, but no prior treatment experience with an HCV NS3/4A PI or NS5A inhibitor; PTV-r: paritaprevir/ritonavir; RBV: ribavirin; SMV: simeprevir; SOF: sofosbuvir; TE: treatment experienced; TN: treatment naive; VEL: velpatasvir; VOX: voxilaprevir.